Background/Aim: Triple negative breast cancer belongs to the most aggressive breast cancer forms. Histone deacetylases (HDACs) constitute a class of enzymes that exhibit a significant role in breast cancer genesis and progression. In this study, we aimed at assessing the clinical importance of HDAC-2 in triple negative breast cancer. Materials and Methods: A total of 138 breast cancer specimens were examined on an immunohistochemical basis. A statistical analysis was performed in order to examine the association between HDAC-2 and the survival and clinicopathological features of the patients. Results: Increased HDAC-2 expression was observed in every fourth case of triple negative breast cancer with positive HDAC-2 staining, whereas only 12 out of 98 non-triple negative breast cancer samples showed high HDAC-2 expression. HDAC-2 overexpression correlated with prolonged overall survival (OS) and disease-free survival (DFS) in triple negative breast cancer. Conclusions: High HDAC-2 levels in triple negative breast cancer seem to positively influence patient survival, disease stage and recurrence.
背景/目的：三阴性乳腺癌属于最具侵袭性的乳腺癌类型。组蛋白去乙酰化酶（HDACs）是一类在乳腺癌发生发展中起重要作用的酶类。本研究旨在评估HDAC-2在三阴性乳腺癌中的临床意义。材料与方法：采用免疫组织化学方法检测138例乳腺癌标本，通过统计分析探究HDAC-2表达与患者生存情况及临床病理特征之间的关联。结果：在三阴性乳腺癌病例中，每四例HDAC-2染色阳性者即有一例呈现HDAC-2高表达，而非三阴性乳腺癌样本中仅12/98例显示高表达。HDAC-2过表达与三阴性乳腺癌患者更长的总生存期和无病生存期显著相关。结论：三阴性乳腺癌中高水平的HDAC-2可能对患者生存率、疾病分期及复发情况产生积极影响。
Evaluation of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
肿瘤(癌症)患者之家